After two U.S. acquisitions back in February, Quotient Clinical has been renamed as Quotient Sciences, and right after that, made another purchase.
U.K.-based CDMO Pharmaterials is now part of the rebranded Quotient Sciences. Quotient said in a release that the acquisition strengthens its formulation and manufacturing services footprint in its home country.
Services offered at Pharmaterials fall within Quotient’s existing portfolio, including characterization and optimization of small-molecule drug physical forms, the development of preclinical and clinical formulations, as well as contract manufacturing for clinical use and commercial supply.
Founded in 2000, Pharmaterials has established 13 GMP manufacturing suites in a 48,000-square-feet facility, which also has more space for future expansion.
Quotient entered the U.S. market through two closely announced acquisitions in February—clinical pharmacology expert Seaview and Charles River Laboratories’ CDMO unit QS Pharma.
“Quotient’s overall strategy behind the acquisitions over the last 12 months is to replicate our Translational Pharmaceutics platform in the USA,” Quotient spokesperson Robin Bodicoat told FierceCRO.
The platform works by combining services from traditional CDMOs with those from CROs, namely integrating formulation development and early-stage clinical research with GMP manufacturing. The company said the approach is proven to reduce drug development costs and shorten timelines.
After these acquisitions, Quotient now has 700 employees working at five sites in the U.S. and the U.K.
By Angus Liu
Source: Fierce Biotech
Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.
Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.
Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.